Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 24;37(4):321-326.
doi: 10.4103/sjopt.sjopt_117_22. eCollection 2023 Oct-Dec.

Intermediate-term outcome of Aurolab aqueous drainage implant in refractory glaucoma

Shanu Mittal  1 , Julie Pegu  1 , Darshana Daga  1 , Suneeta Dubey  1
Affiliations

Intermediate-term outcome of Aurolab aqueous drainage implant in refractory glaucoma

Shanu Mittal et al. Saudi J Ophthalmol. .

Abstract

Purpose: The purpose of the study was to evaluate the intermediate-term outcomes of Aurolab aqueous drainage implant (AADI) in terms of intraocular pressure (IOP) lowering from baseline levels, the number antiglaucoma medications (AGMs) in the postoperative phase, and the rate of complications.

Methods: It was a retrospective interventional case series. All patients who underwent AADI surgeries with sulcus fixation from March 2018 to September 2018 at a tertiary eye care hospital in North India with a minimum follow-up of 1 year were recruited for the study. A standard AADI technique was employed. The primary outcome measures were the postoperative IOP, the requirement of AGMs, and early and late postoperative complications.

Results: A total of 20 patients were recruited in the study. The mean follow-up period was 25.25 ± 3.76 months. The mean IOP reduced from 33.20 ± 7.95 mmHg to 19.45 ± 9.19 mmHg at day 1, 13.62 ± 3.92 mmHg at 6 months, 12.78 ± 3.36 mmHg at 1 year, and 13.0 ± 2.53 mmHg at 2 years postoperatively (P < 0.001). The mean number of AGMs also reduced from 3.7 ± 0.97 to 0.35 ± 0.81 at 6 months, 0.42 ± 0.83 at 1 year, and 0.26 ± 0.73 at 2 years postoperatively (P < 0.001). Early postoperative complications, such as hypotony and hyphema, were seen in 5 (25%) patients, although none of them was sight-threatening. Late postoperative complications, such as hypertensive phase and persistent fibrinous membrane, were also seen in five eyes.

Conclusion: The study assessed the clinical outcomes, safety profile, and long-term AGM requirement with AADI and found it to be a good viable surgical option in refractory glaucoma.

Keywords: Aurolab aqueous drainage implant; glaucoma drainage device; refractory glaucoma.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Intraocular pressure trends after Aurolab aqueous drainage implant
Figure 2
Figure 2
Mean antiglaucoma medications after Aurolab aqueous drainage implant
Figure 3
Figure 3
Postoperative outcome after Aurolab aqueous drainage implant
See this image and copyright information in PMC

References

    1. Ashburn FS, Netland PA. The evolution of glaucoma drainage implants. J Ophthalmic Vis Res. 2018;13:498–500. - PMC - PubMed
    1. Senthil S, Gollakota S, Ali MH, Turaga K, Badakere S, Krishnamurthy R, et al. Comparison of the new low-cost nonvalved glaucoma drainage device with Ahmed glaucoma valve in refractory pediatric glaucoma in Indian eyes. Ophthalmol Glaucoma. 2018;1:167–74. - PubMed
    1. Archana S, Premanand C, Raman GV. Aurolab aqueous drainage implant:My surgical technique. Kerala J Ophthalmol. 2017;29:41–5.
    1. Pathak Ray V, Rao DP. Surgical outcomes of a new affordable non-valved glaucoma drainage device and Ahmed glaucoma valve:Comparison in the first year. Br J Ophthalmol. 2019;103:659–65. - PubMed
    1. Philip R, Chandran P, Aboobacker N, Dhavalikar M, Raman GV. Intermediate-term outcome of Aurolab aqueous drainage implant. Indian J Ophthalmol. 2019;67:233–8. - PMC - PubMed